Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the ceo or management has the record of all the shareholders on record.
as for who owns the 110 million shares,, the ceo and CFO knows.
how you think dividends are paid to shareholders.
there is shareholder record of date and that info the company has it.
only 36 million of the shares are freely traded or registed to be traded
the 110 million share ownership is private information not disclosed publicly
you cannot buy all the shares of the company in the open market to have control of the company as only 36 million is publicly available to buy so no way anyone can buy all the shares in the open market or exchange to control the company or have any say in corporate matters. even if you own 36 million shares or all the freely traded shares, you still cannot have a seat in the board of directors or no say in the company.
and who owns 110 mm shares ?
delusion runs wild here
white collar crime like corporate embezzlement or political corruption is very hard to investigate or prosecute criminal charges without insider ratting or tips. normally the person just get fired from the job. rather than charged for 'embezzlement'. Today the corruption and embezzlement is in your face and getting more obvious and cannot be ignored like in mexico and country becomes failed state .
this entire trial is like watching a play....talking non-sense. with fake bankrupty filing
I'm in the process of reading today's Order issued by the bankruptcy court judge. Taking a break for dinner, so here is the link.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1089767&projectCode=HUM&docketNumber=309&source=DM
today zero volume
now one guy still owns 110 million shares and
still not sell his 110 million worth less shares?
this is what I call an illiquid market ZERO volume
not to mention dales insider trading, he should be behind bars to be frank. he benefited abnormally well for an insider
you can say management 'embezzled' corporate assets.
corporate embezzlement is grey area in white collar crime, the actions can be legal or illegal.
depending on the circumstance like pay 100x more than market value for services and products. or paying elon musk 56 billion in salary and say it was worth it. and he was paid fairly. and that board of directors approved it. when the ceo tells the board of directors what to do. or how to vote, it's called rigged vote. only one check box. like a shell game, you give three choices. or picks, all picks is same answer. the company is shell company that is now being dissolved and hgenq shares deregistered.either a new company is created and old shareholders may be getting new shares is how some corporate restructiuring occurs to avoid any legal issues.
this entire waste of time 6 months chapter 11 was unnecesssary and smoke and mirrors, the hgenq bankrupt company spent over 1 million of company cash in legal fees. in the beginning of the chapter 11 it had 3 million in cash. and only 5 million in 'liabilities' that is not disputed like payament serives 'rendered' or payment for bills completed like rent and taxes. etc.
it was not bankrupt. and could have easily raised 10 million in new equity and continued it's FDA application. but going bankrupt or declaring chapter 11 was the plan from the beginning and buy(steal) the ip asssets for free.
ok that’s different than some non existent illegal hidden share scheme (s)
the shareholders largest benefactor, dale , already cashed in on his investment. i question his motivation at this moment
like i said earlier the next we hear from durrant will tell us everything we need to know .
Without regulatory approval, or news of a partnership, etc., we're where we are.
let me just say for all practical purposes…
if these guys actually intend to unfold your theory of hidden loaned shares , after a bankruptcy proceeding where they said they were essentially broke, then they will probably have a few three letter agencies lined up
to answer to.
again nothing more than fanciful speculation
Agreed, everything he posts is from another company, with a conspiracy that we are going to merge, be bought out etc. Teran has the asset, management has been missing for years, it's over. 100% over
and you saw it on this website if i recall?
Actually, dlog, there was data in that regard, which I suspected, at the time, was from our Transfer Agent, to the NASDAQ Hearing Panel.
jay there is no evidence to support your claims that there will be any share recall nor that the company owns 192% of the shares.
this is made up in your head
i believe you think just because shkreli did it , that these guys will do the same.
its just silly
at least you are no longer talking about the forward split so perhaps there is hope for you
I mention the following should it be worth doing so.
"To me, part of the reason for investing here has always been a stock play, such (as) they executed previously DBA Kalobios."
I've never considered the PPS as reflective of the value of the stock. The value I have always considered was based on the projected value, when management recalls their loaned shares. It is for this reason that I have maintained open sell orders priced at $200.
Therefore, it is not mere ownership of shares that constitute my Equity Claim. My equity claim is based on a stated float that was reported at 192% of the Outstanding Shares, and knowing that excess shares in the market will have to be bought-in, in the event of a recall of the loaned shares, or a merger.
see pgs 4-5/26
"A. Equity Claims
13. The Debtor objects to the Equity Claims identified on Exhibit A to the Proposed Order because such claims relate solely to the mere ownership of equity security interests in the Debtor (as opposed to a claim arising from such ownership). Therefore, the Equity Claims do
not constitute a “claim” within the meaning of section 101(5) of the Bankruptcy Code. "
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1079544&projectCode=HUM&docketNumber=254&source=DM
Having said the above, I recognize that no recall of the loaned shares has yet been issued, nor has a merger been announced. However, management has to maintain control of a possible distribution to equity holders, even if motion is made to convert the bankruptcy to CH7.
chapter 11 of filing for banktupcy is a very simple basic process.
creditors force you to sell all assets that you own. if the proceeds is less than that is owed. it's the creditors problem
after chapter 11 the corporation or person has no debts. and is cleared.
that is how bankruptcy chapter 11 works. after all the assets are sold any if any money is paid to the creditors, in this case, there is no money to pay anyone. less than 1 million so that 40 million 'fake liability' against the assets get nothing as all the money is in some 'trust' fund. funds in at trust are impossible to get out without the approval of the trustee. trust fund have a charter saying how the money is paid out too. but that is if the trustee can be trusted. lots of trust funds, the trustee bills the trust fund like percentage of value of assets or annual 'management fee' and sometimes the management fee is so high after a few years, there is no money in the fund. there is less than $500,000 in the fund if the trustee is billing the fund $200,000/year, plus trust fund expenses all the money is gone in a year.
what don't you understand,
the hgenq corporation sold all it's ip assets for nothing.
hgenq has been in DIP debtor in possession means the creditors have seized all assets and auctioned it off to REPAY 'creditor claims' whether those 'disputed' creditor claims are valid was not disputed by hgenq.
and no need to dispute any disputed claim since the creditors get nothing as their is nothing to repay them of any claims they claim. the law suite for the .046/share settlement they are in the same line as the 100 other fake creditor claims.
I don't know what you're talking about, but neither do you. And you're certainly not in position to determine the validity of the claims against the company. The chief invalid claim is that the ACTIV-5 trial did not corroborate the results of the LIVE-AIR trial. The truth is, the ACTIV-5 trial was designed to fail, and failure to meet the endpoint of that trial of late-stage patients, had nothing to do with the successful treatment of the early-stage LIVE-AIR patients. And the class action tort lawyers who brought suit against the company were totally derelict in their duty.
Your reply failed to address the issue I presented in my post. What does that information mean to you?
My concern was in regards to the Liquidation Trustee having sole discretion to declare a distribution to existing equity holders. It seems to me that Humanigen management shares that concern, and their objection still appears to be on tomorrow's docket. I think they intend to safeguard claims of equity interest accounts, not only on shareholders' behalf, but on Humanigen's behalf, as well, since I think they control ~90% of our Outstanding Shares.
https://document.epiq11.com/document/getdocumentbycode?docId=4343828&projectCode=HUM&source=DM
FDA approves Merck pneumococcal disease vaccine designed for adults https://www.cnbc.com/2024/06/17/fda-approves-merck-pneumococcal-disease-vaccine-designed-for-adults.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
to defend yourself against fake creditor claims would cost additional legal fees and that is itself a legal harassment with false accusations with false claims. In many countries making false charges or lawsuits is illegal. it's considered legal harassment. Trump trial is common political persecution with fake charges and fake blown charges for political gains. the charges or claims of crime or harm by complainant is obviously unreasonable and bogus. and penalty doesn't meet the punishment or fine doesn't justify the CRIME or monetary, or harm the complainant received. that is the symbolism of the lady wearing blind around here eyes and weighs the harm and punishment to carry out justice, an eye for an eye. or the PUNISHMENT must equal the HARM done. or using the balance scale of justice. your weigh the harm or real harm and give a sentence. that is 'reasonable' and 'fair' without biases or prejudice. or the law is blind
in most cases, it's much easier to just declare chapter 11 or bankruptcy for man companies or individuals than object to fake creditor claims.
in bankruptcy, some people just sell all their assets before declaring bankruptcy or transfer all assets to another country then go to court to dispute fake claims like 100 million dollar fine for 'defamation' in social media CRIME. the judge who gave the $100 million fine knows the fine was just a token that the accused is guilty and complainant won't get a dime of her 'complaint' that she was wronged or harm in CIVIL COURT and get this clown case out of he court and stop wasting the gov't and judge time is this bogus trial.
"Docket # 254
Filed May 03 2024
First Omnibus Objection to Claims //Debtor's First Omnibus Objection (Non-Substantive) to Claims on Account of Equity Interests. Filed by Humanigen, Inc.. Hearing scheduled for 6/13/2024 at 10:00 AM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #1, Wilmington, Delaware. Objections due by 5/17/2024. (Attachments: # (1) Notice # (2) Exhibit 1 # (3) Exhibit 2) (Forshay, Shannon)
Case Number 24-10003 Humanigen, Inc."
4th tab
https://dm.epiq11.com/case/humanigen/dockets
Always best to remain up to date. But prior to the years I spent here, I spent years in another company, where the SEC totally abused their discretionary authority, as they likely did here, and as NIAID/NIH, and the FDA definitely did. And the much more extensive research I did in the other company showed just cause to a judge to grant me subpoena power, which I used. So time I don't have to spend in the weeds, because of research from people like you, is very much appreciated.
So I assume the Omnibus Hearing and the Governmental Bar Date, whatever those are, are likewise delayed.
Like I see you did, I credited US-JUSTICE for his valid points, but he then tends to get sidewise in keeping with what I suspect is his agenda, and it only diminishes whatever credibility he had. The government's abuse of discretionary authority is one thing, when the SEC uses it to fund recipients of government largesse from the Treasury Dept. The abuse of discretionary authority by NIAID, the NIH, and the FDA, causes the preventable loss of life, and that is a worthy cause to fight.
This is the first post I have read from you with a legitimate substance to it surrounding the company and the stock. Unfortunately, you had to do it while also being rude to another person....which I honestly just don't understand.
Anyway, I believe you are correct about the hearing date change which can be seen at the site I posted. I had not mentioned the postponement prior because the only place that actually said those words was the Delaware bankruptcy court calendar page which stopped working for our presiding judge within hours of the alteration (go figure) and I hadn't taken a screenshot.
Thank Jay.
I've been a long-time stockholder and board reader prior to posting, and have done my due diligence and best to remain up to date.
I really appreciate when other stockholders, such as SorcererGuru44, contribute valuable research. I've been following this company since 2015, invested since it became Humanigen in 2017, and I have previously said that I have had my fill of legal boilerplate. I'll take the CliffNotes version, with links, anytime.
https://dm.epiq11.com/case/humanigen/dockets
Cowtown is either paid troll or stock 'cheerleader' . because if he was that dedicated and did his 'homework' and due diligence to this ticker he would know that the hearing for june the 13 was cancelled and postponed to june 18,2024
the guy would not waste time reading the over 300 documents. which 3/4 of it's just adminstrative filings that nobody reads it. only 10 documents is of any relevancy to this case.
hgenq as a BANKRUPT company somehow spent over 3 million in the last two years in legal fees and company has only 4 employees.
you be surprise who many people would just buy $20,000 of a stock and don't even read the SEC reports of a company and call that an 'investment' people spend more time shopping around for a $300 air conditioner than a $10,000 investment
I wish there was news. I've been wishing for news ever since we filed our topline data from the LIVE-AIR trial in March of 2021, just one year after covid hit our shores. That was an incredible achievement, especially for a small-cap biotech. Lenz could have saved the lives of many who were lost; it could have improved the quality of life in patients that couldn't be saved; and it could also have improved the quality of life of those of us who invested here. I think management is steadfast in their effort to achieve success, and I owe them support in their quest.
6/13 has come and gone where's this "news"?
That's actually good to know, SorcererGuru44. Sanofi may not be quite ready to spinoff until next quarter, which, as you said, "...may or may not mean anything to us."
Appreciate your research.
I have only found information regarding Dundon Advisers becoming the liquidating trustee in one other chapter 11 liquidation case.
I believe there are at least a few more, I just cannot find additional info on them. The one I am able to research is still in business, they are still the liquidating trustee, and they seem to be doing alright - at least based on the minimal filings I was able to review from the past few months.
That may or may not mean anything to us. Just interesting to point out.
Management dutifully reported the clinical safety and efficacy results of lenz in treating/preventing CMML in the PREACH-M study, as well as the outstanding Hazard Ratio of 2.54, as determined by the Thorax peer review of the LIVE-AIR trial for covid.
The IP was devalued by the NIAID/NIH ACTIV-5/BET-B trial design and orchestrated results.
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Receives-Preliminary-Topline-Data-From-NIHNIAID-Study-of-Lenzilumab-in-ACTIV-5BET-B/default.aspx
So the issue is not my claiming an overstated value of the IP in the billions. That was, is, and will be the value.
You have shown no interest in the real issue that decimated the value of this life-saving therapeutic, nor in the willful/criminal negligence of the NIAID/NIH and FDA, which continues to permit the preventable loss of life. I don't understand why you wouldn't want to give this issue serious attention, and quit wasting your ability.
Before the 1930's, most policing was the city level. there was no FBI for federal crimes. and no SEC, SEC has failed Americans in such things as investment fraud as crimes in the market and exchange requires expertise in the inudstry. And it's easier to corrupt local judges and police than some out of state agency like the FBI as FBI staff changes all the time and much bigger unlike local police or local judges. Even the hiring and appointment of judges in the local level is corrupt or nepotism or based on 'loyalty' rather than credentials and much easier to corrupt or bribe local gov't than federal gov't
Board of directors fudiciary failure like the board of directors in Tesla actually 'approved' paying Elon 45 billion salary because if they don't he'll quit.?
the board of directors were forced or bribed to vote yes. to elons 45 billion. now this is in very high profile real company not a penny stock, now if these people can be that corrupt in tesla and run the company like some penny stock... they even got the media outlets all bribed to not critize elon's corporate embezzlement of 45 billion as not illegal or wrong.
The fact is the ip asset you claim to be worth billions or worth anything was sold for nothing or zero value in a rigged auction. nobody could be for it. and the company didn't solicit any bids in the 6 months it claimed to have marketed the assets to interested buyers.
I actually believe that our likelihood of success is MORE realistic now than it has ever been. Sanofi is a behemoth, and 100% capable of meeting all of our manufacturing and other CMC requirements. Even more, they have 77 projects in their active pipeline, to include therapeutic development for:
Immunology & Inflammation
Neurology
Oncology, and
Rare Diseases
I think lenz could be market-dominant in all these areas.
So there are numerous opportunities for lenz to enhance or replace the therapeutics that are already in these many clinical trials. Some of these trials are for the same indications that lenz, and Ifab, are already being developed for, such as AML, (CMML for us) GvHD, and solid tumors.
https://www.sanofi.com/en/our-science/our-pipeline
And I'm hoping that Dubovsky can help us capture foreign regulatory approval and commercialization of lenz for covid through the vast network Novavax has worldwide. In fact, Novavax is current with domestic competitors for the 2024-2025 vaccine year, and they will again have the only non-mRNA vaccine in the US.
So when the Milestone Events were amended to be significantly expanded, I think much of this increased opportunity will stem from our role in the Sanofi/Novavax entity that will follow Sanofi's spinoff.
I eagerly await a Press Release in these matters, and I look forward to the recall of our loaned shares
“If overseas traders who are aware of the potential for Lenz approval aren’t trying to sell shares, it kinda tells you all ya need to know? “
Not really the same thing, you have a sell order in place that is way above any
Pps level else we have seen in years. It’s not going to fill in the state that HGENQ is in right now. I could put in a sell order for .05 tomorrow and it won’t fill, no one will buy those shares for even a nickel at this point,
Those who aren’t selling like myself see it as a wasted chance at a gamble that may play out, the old saying of “a chip and a chair” and know it’s pointless to sell at this point anyway.
As always I like your optimism, finding less realistic at this point but crazier things have happened.
I did sell nearly a million ALPP shares at .06 to buy more HGEN during COVID…ALPP ran to $9.00 shortly there after….Durrant owes me a mulligan haha!
That looks like it leans in Jay's direction.
Liquidating trustee is Dundon Advisers LLC, which incidentally specialize is restructuring.
"If overseas traders who are aware of the potential for Lenz approval aren’t trying to buy shares, it kinda tells you all ya need to know."
Doesn't that logic equally apply to sellers, such that:
If overseas traders who are aware of the potential for Lenz approval aren’t trying to sell shares, it kinda tells you all ya need to know?
I don't think that investor sentiment can adequately be reflected on the Expert Market, where Bid/Ask information is not displayed.
I don't want to downplay the situation we are now in, which is being placed in liquidation status, versus reorganization status. I don't know who the Liquidating Trustee is. No do I know if this is a management-supported defensive tactic. But I don't accept that he has unfettered authority to use "sole discretion," as is reported. An offer of Taran shares, for HGEN shares, for example, should prompt the judge to disallow liquidation. And more, the announcement of regulatory approval of lenz to treat or prevent CMML and/or aGvHD, should result in more than enough funds for management to fully meet obligations to the Unsecured Creditors, and result in the discharge of this case from the bankruptcy court.
Anything less than a distribution to existing equity holders, this close to our success, would transcend a mere travesty of justice. It would be illegal under the circumstances I just described.
as for the stock one guy still owns 110 million shares of some worthless shares. he needs the chapter 11 to conclude and hot ip assets to be sold and liquidated and shares of hgenq shares cancelled and dissolved before he sells his 110 million shares.
banning americans from buying stock but allow foreigners to buy the stock due to regulations.
but if americans can still buy the stock if they know someone in another country and do OTC contract or swap to buy the stock on their behalf. it has to do with SEC regulations which apply only to american brokerage/dealer accounts not foreign brokerage/dealer accounts.
any american can just open LLC account in some foreign brokerage account and buy these shares, but why.?
I guess foreigners have much more difficult in sueing an american company or american and file civil or criminal charges.
It much harder for a foreigner to sue an american, you have to be physically in court to file the charges. but much easier for an american to sue another american in civil court that is why SEC bans Americans from buying these stocks.
if you wired money to some country in another country it's next to impossble to get the money back, but if the person resides in US and money is still in the country, you can still get it back with lawsuit etc. but if the person is another country, the cops in another country won't even answer your emails that you got ripped off.
finally some common sense
I honestly feel that if there was anything left here, if there were any chance of recovery for commons we wouldn’t be trading at these levels. HGEN and Lenz are known overseas, no chance that traders overseas who see this as a viable play for any returns wouldn’t be trying to buy shares that US traders are excluded from buying.
If overseas traders who are aware of the potential for Lenz approval aren’t trying to buy shares, it kinda tells you all ya need to know. This will be great for Tarran and Durrant, even Dale, for commons in HGENQ, I think it’s done and on its way to getting revoked.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
7
|
Posts (Total)
|
43265
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |